

**Medscan 3D Limited**  
**Abridged Unaudited Financial Statements**  
**for the financial year ended 31 December 2025**

**Medscan 3D Limited**  
**CONTENTS**

	<b>Page</b>
Directors' Responsibilities Statement	3
Balance Sheet	4
Notes to the Financial Statements	5 - 7

# Medscan 3D Limited

## DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 December 2025

The directors made the following statement in respect of the unaudited financial statements:

### "General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that they have made available to Lillis Egan O Beirn & Co, (Chartered Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 31 December 2025."

### Signed on behalf of the board

**James Wall**  
Director

**9 March 2026**

**Jacqueline O'Connor**  
Director

**9 March 2026**

**Medscan 3D Limited**  
**BALANCE SHEET**

as at 31 December 2025

	Notes	2025 €	2024 €
<b>Current Assets</b>			
Debtors	5	362	400
<b>Creditors: amounts falling due within one year</b>	6	-	(38)
		<u>362</u>	<u>362</u>
<b>Net Current Assets</b>		<u>362</u>	<u>362</u>
<b>Total Assets less Current Liabilities</b>		<u><u>362</u></u>	<u><u>362</u></u>
<b>Capital and Reserves</b>			
Called up share capital presented as equity		100	100
Retained earnings	7	262	262
<b>Equity attributable to owners of the company</b>		<u><u>362</u></u>	<u><u>362</u></u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Medscan 3D Limited, state that -

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied,
- (c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

**Approved by the board on 9 March 2026 and signed on its behalf by:**

**James Wall**  
**Director**

**Jacqueline O'Connor**  
**Director**

# Medscan 3D Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

### 1. General Information

Medscan 3D Limited is a company limited by shares incorporated in Ireland. The registered office of the company is Mill House, 10 Mill Street, Galway.

The nature of the company's operations and its principal activities are set out in the Directors' Report.

Medscan 3D Limited is a wholly owned subsidiary of De Bhal Medical Limited, which is also a company registered in Ireland with a registered office of Mill House, 10 Mill Street, Galway.

The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### Statement of compliance

The financial statements of the company for the financial year ended 31 December 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

#### Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

#### Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

#### Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

**Medscan 3D Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
for the financial year ended 31 December 2025

**Financial Instruments**

**Ordinary share capital**

The ordinary share capital of the company is presented as equity.

**Other financial assets**

Other financial assets including trade debtors arising from goods sold to customers on short-term credit, are initially measured at the undiscounted amount of cash receivable from that debtor, which is normally the invoice price. If payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate, this constitutes a financing transaction, and the financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Subsequently, other financial assets are measured at amortised cost less impairment, where there is objective evidence of impairment.

**Other financial liabilities**

Other financial liabilities, including trade creditors arising from goods purchased from suppliers on short-term credit, are initially measured at the undiscounted amount owed to the creditor, which is normally the invoice price. Liabilities that are settled within one year are not discounted. If payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate, this constitutes a financing transaction, and the financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Subsequently, other financial liabilities are measured at amortised cost.

**3. Significant accounting judgements and key sources of estimation uncertainty**

There are no significant judgements in applying the accounting policies or significant area of estimation uncertainty.

**4. Employees**

The average monthly number of employees, including directors, during the financial year was 2, (2024 - 2).

	<b>2025</b>	2024
	<b>Number</b>	Number
Directors	<b>2</b>	2

**5. Debtors**

	<b>2025</b>	2024
	<b>€</b>	€
Amounts owed by group undertakings	<b>323</b>	400
Taxation	<b>39</b>	-
	<b>362</b>	400

Amounts owed by connected parties are unsecured, interest free, have no fixed date of repayment and are repayable on demand.

**6. Creditors**  
**Amounts falling due within one year**

	<b>2025</b>	2024
	<b>€</b>	€
Taxation	-	38

Taxation is payable in the timeframe set down in the relevant legislation.

**Medscan 3D Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
for the financial year ended 31 December 2025

**7. Profit and loss account**

	<b>2025</b>	2024
	€	€
At 1 January 2025	<b>262</b>	-
Profit for the financial year	-	262
	<u>262</u>	<u>262</u>
At 31 December 2025	<b>262</b>	262
	<u>262</u>	<u>262</u>

Profit and loss represents accumulated comprehensive income for the current financial year and prior periods.

**8. Capital commitments**

The company had no material capital commitments at the financial year ended 31 December 2025 (2024 - €Nil).

**9. Directors' remuneration**

No Directors' remuneration was paid in the financial year (2024 - €Nil). There are no other key management personnel in addition to the directors.

**10. Related party transactions**

The inter group balance of €323 relates to the subscription of shares in Medscan 3D Limited by De Bhál Medical Limited and the net trading transactions with the connected company Advanced Three D Technology Limited, which is also a subsidiary of De Bhál Medical Limited.

**11. Parent company**

The company regards De Bhál Medical Limited as its parent company.

The parent of the largest group in which the results are consolidated is De Bhál Medical Limited.

**12. Controlling interest**

The company is controlled by James Wall and Jacqueline O'Connor, both directors of the company, as controlling parties of the parent company De Bhál Medical Limited.

**13. Post-Balance Sheet Events**

There have been no significant events affecting the company since the financial year end.

**14. Approval of financial statements**

The financial statements were approved and authorised for issue by the board of directors on 9 March 2026.